<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124955</url>
  </required_header>
  <id_info>
    <org_study_id>FDAAAAU</org_study_id>
    <nct_id>NCT01124955</nct_id>
  </id_info>
  <brief_title>Acupuncture Using Yamamoto's Method for the Treatment of Acute Nonspecific Low Back Pain</brief_title>
  <acronym>ANLBP</acronym>
  <official_title>Acupuncture for Acute Nonspecific Low Back Pain: a Randomized, Controlled, Double-blind, Placebo Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to assess the effectiveness of acupuncture using Yamamoto's
      method for the treatment of ANLBP using the following outcomes:pain,functional
      capacity,quality of life and number of 50 mg sodium diclofenac pills taken per day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, controlled, double-blind, prospective trial is being conducted involving 80
      patients with low-back pain defined as pain and discomfort localised bellow the costal margin
      and above the inferior gluteal folds, for a period of less than 30 days and unrelated to any
      specific etiological factors. Patients are being recruited from the university hospital of
      the Federal University of Sao Paul (UNIFESP)and exams were carried out by a rheumatologist.
      The patients are randomly assigned to either intervention group (IG) and are submitted to
      five acupuncture sessions or placebo group (PG) and are submitted to five non-penetrating
      acupuncture sessions. Both groups are recommended to take 50 mg of sodium diclofenac every
      eight hours for lumbar pain, if needed and record the number of pills on a standardized form.

      The patients are instructed not to use other medications or therapies for low-back pain
      during the study.The IG are submitted to acupuncture by a physician acupuncturist with eight
      years experience in the technique. Five acupuncture session are performed at baseline, D3,
      D7, D14 and D21. Specific needles for scalp acupuncture and tubes that guide these needles,
      called mandrels are unpacked in front of the patient. The stainless steel needles: 0.20 x 13
      mm, sterilized and disposable.Sessions last 20 minutes. The patient remain seated, using a
      hat with a central orifice exposing the area to receive the needles. The hat has a wide brim
      to keep the patient blinded for the procedures. The needle penetrates the skin at an
      approximately 15º angle and a depth of 0.3 to 0.5 cm. The PG are submitted to five placebo
      acupuncture session performed by the same acupuncturist with same material and hat, but
      penetration did not occur and only the mandrel came into contact with the skin. All patients
      are blind to which procedure they are receiving. The basic points D, H and I and kidney,
      bladder and liver points of Yamamoto's method are used as standard treatment to ANLBP for the
      both groups.

      Evaluations: The IG and PG are evaluated six times between baseline and Day 28 immediately
      before and after each acupuncture session. Outcome measures are recorded by a single assessor
      blinded to group allocation.

      D0: baseline; D3: three days after baseline; D7: seven days after baseline; D14: fourteen
      days after baseline; D21: twenty-one days after baseline and D28: twenty-eight days after
      baseline.

      Losses: Participants absent from more than three acupuncture sessions and evaluations are
      considered losses.

      Placebo credibility: At the end of the study, participants are asked about which group they
      believed they belonged.

      Sample size: To achieve an improvement in VAS pain of 2.0 point, with a significance of 0.05,
      and a power of 0.90, a minimum of 40 patients per group is necessary as a previous
      compensation for the possible 20% loss at follow-up.

      Statistics: An intention-to-treat analysis are performed, using the
      last-observation-carried-forward method. A level of significance of p &lt; 0.05 (2-tailed tests)
      are accepted for the trial. For normally distributed data, the variables are analysed using
      repeated-measures analysis of variance (ANOVA). The analysis are performed between groups
      (acupuncture versus non-penetrating acupuncture; between subjects factors) and over the time
      (baseline, 3, 7, 14, 21 and 28 days; within subjects factors). Categorical data measured over
      time are analysed using repeated-measures analyses of variance (ANOVA) for categorical data.
      A 95% confidence interval (95% CI) are used. The Student's t-test are used to compare
      numerical variables with normal distribution at one time and the chi-square test or Fisher's
      exact test are used to determine differences in rates of improvement between the two groups.
      The Kappa index are used to determine agreement on the LIKERT assessment between patient and
      assessor. All tests are performed using SPSS version 15.0 and MINITAB 14.0
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Assessed on a 10-point Numeric Pain Scale</measure>
    <time_frame>days 0, 3, 7, 14, 21 and 28</time_frame>
    <description>The primary outcome is a visual analog pain scale (VAS), graded in centimeters from 0 to 10 (0=no pain; 10=worst imaginable pain), measured before (VAS 1) and after (VAS 2) the acupuncture session.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Roland-Morris Disability Questionnaire (RM)</measure>
    <time_frame>days 0, 3, 7, 14, 21 and 28</time_frame>
    <description>Secondary outcomes includes the Roland-Morris Disability Questionnaire (RM) for the assessment of functional capacity, with 24 items on low-back pain: higher scores denote poorer functional capacity.
0: better functional capacity 24: poorer functional capacity Range of score: the highest is 24 (poorer functional capacity) and lowest scores is 0 (better functional capacity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessed on the SF-36</measure>
    <time_frame>Days 0, 3, 7, 14, 21 and 28</time_frame>
    <description>Questionnaire Short-form-36 is a widely used generic health status questionnaire, validated for Portuguese with eight components and each components with scores from 0 to 100: higher scores denote greater quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likert Improvement Assessment Scale</measure>
    <time_frame>Days 0, 3, 7, 14 and 21</time_frame>
    <description>Likert improvement assessment scale is based on the patient's opinion (LIKERT P) and assessor's opinion (LIKERT A), categorized in 1=MB (much better), 2=SB (slightly better), 3=NC (no change), 4=SW (slightly worse) and 5=MW (much worse). This scale was was applied to each day of assessment. The numbers in the category titles represent the different days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Anti-inflammatory Tablets Taken</measure>
    <time_frame>Days 3,7,14,21 and 28</time_frame>
    <description>Number of 50 mg sodium diclofenac pills taken per day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 5 sessions of real acupuncture. The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-penetrating acupuncture</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)</description>
    <arm_group_label>Intervention Group</arm_group_label>
    <other_name>Real acupuncture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-penetrating acupuncture</intervention_name>
    <description>The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.</description>
    <arm_group_label>Non-penetrating acupuncture</arm_group_label>
    <other_name>Placebo acupuncture</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Aged 18 to 65 years

          -  Seeking medical assistance for nonspecific low-back pain

          -  Score of 4 to 8 cm on the pain scale (0 to 10 cm)

          -  Agreed to participate and signed term of informed consent

        Exclusion Criteria:

          -  Patients with a diagnostic investigation of secondary causes as spondyloarthropathy,
             infection, tumor or fracture

          -  Sciatica lumbar pain

          -  Previous surgery on spinal column

          -  Litigation

          -  Having changed physical activity or underwent acupuncture or physical therapy in
             previous three months,

          -  Having previously undergone scalp acupuncture

          -  Pregnancy

          -  Contraindication for anti-inflammatory agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamil Natour, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tatiana Hasegawa</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04011060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tatiana Hasegawa</name>
      <address>
        <city>São Paulo</city>
        <zip>04011-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Inoue M, Hojo T, Nakajima M, Kitakoji H, Itoi M. Comparison of the effectiveness of acupuncture treatment and local anaesthetic injection for low back pain: a randomised controlled clinical trial. Acupunct Med. 2009 Dec;27(4):174-7. doi: 10.1136/aim.2009.001164.</citation>
    <PMID>19942724</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2010</study_first_posted>
  <results_first_submitted>August 9, 2010</results_first_submitted>
  <results_first_submitted_qc>May 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2011</results_first_posted>
  <last_update_submitted>June 13, 2011</last_update_submitted>
  <last_update_submitted_qc>June 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tatiana Molinas Hasegawa</name_title>
    <organization>Federal University of Sao Paulo</organization>
  </responsible_party>
  <keyword>treatment</keyword>
  <keyword>acupuncture</keyword>
  <keyword>spine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>100 patients were recruited from the university hospital of the Federal University of São Paul (UNIFESP), from November 2009 to June 2010.</recruitment_details>
      <pre_assignment_details>80 patients were randomized during the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acupuncture</title>
          <description>The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Patients were submitted to five non-penetrating acupuncture sessions in the placebo group (PG).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acupuncture</title>
          <description>The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Patients were submitted to five non-penetrating acupuncture sessions in the placebo group (PG).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="9.8"/>
                    <measurement group_id="B2" value="43.9" spread="10.9"/>
                    <measurement group_id="B3" value="45.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Assessed on a 10-point Numeric Pain Scale</title>
        <description>The primary outcome is a visual analog pain scale (VAS), graded in centimeters from 0 to 10 (0=no pain; 10=worst imaginable pain), measured before (VAS 1) and after (VAS 2) the acupuncture session.</description>
        <time_frame>days 0, 3, 7, 14, 21 and 28</time_frame>
        <population>Intention to treat analysis (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Acupuncture</title>
            <description>The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients were submitted to five non-penetrating acupuncture sessions in the placebo group (PG).</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assessed on a 10-point Numeric Pain Scale</title>
          <description>The primary outcome is a visual analog pain scale (VAS), graded in centimeters from 0 to 10 (0=no pain; 10=worst imaginable pain), measured before (VAS 1) and after (VAS 2) the acupuncture session.</description>
          <population>Intention to treat analysis (ITT)</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cm</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.55" spread="1.4"/>
                    <measurement group_id="O2" value="6.68" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="2.23"/>
                    <measurement group_id="O2" value="5.13" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="2.61"/>
                    <measurement group_id="O2" value="4.4" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.27"/>
                    <measurement group_id="O2" value="3.95" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="2.4"/>
                    <measurement group_id="O2" value="4.18" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="2.12"/>
                    <measurement group_id="O2" value="3.38" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Roland-Morris Disability Questionnaire (RM)</title>
        <description>Secondary outcomes includes the Roland-Morris Disability Questionnaire (RM) for the assessment of functional capacity, with 24 items on low-back pain: higher scores denote poorer functional capacity.
0: better functional capacity 24: poorer functional capacity Range of score: the highest is 24 (poorer functional capacity) and lowest scores is 0 (better functional capacity).</description>
        <time_frame>days 0, 3, 7, 14, 21 and 28</time_frame>
        <population>Intention to treat analysis (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Acupuncture</title>
            <description>The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients were submitted to five non-penetrating acupuncture sessions in the placebo group (PG).</description>
          </group>
        </group_list>
        <measure>
          <title>Roland-Morris Disability Questionnaire (RM)</title>
          <description>Secondary outcomes includes the Roland-Morris Disability Questionnaire (RM) for the assessment of functional capacity, with 24 items on low-back pain: higher scores denote poorer functional capacity.
0: better functional capacity 24: poorer functional capacity Range of score: the highest is 24 (poorer functional capacity) and lowest scores is 0 (better functional capacity).</description>
          <population>Intention to treat analysis (ITT)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>scores on a scale</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="4.0"/>
                    <measurement group_id="O2" value="14.6" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="5.4"/>
                    <measurement group_id="O2" value="12.4" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="5.5"/>
                    <measurement group_id="O2" value="10.2" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="4.6"/>
                    <measurement group_id="O2" value="8.9" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="4.4"/>
                    <measurement group_id="O2" value="8.5" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="4.7"/>
                    <measurement group_id="O2" value="8.0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0,05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessed on the SF-36</title>
        <description>Questionnaire Short-form-36 is a widely used generic health status questionnaire, validated for Portuguese with eight components and each components with scores from 0 to 100: higher scores denote greater quality of life.</description>
        <time_frame>Days 0, 3, 7, 14, 21 and 28</time_frame>
        <population>Intention to treat analysis (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Acupuncture</title>
            <description>The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients were submitted to five non-penetrating acupuncture sessions in the placebo group (PG).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessed on the SF-36</title>
          <description>Questionnaire Short-form-36 is a widely used generic health status questionnaire, validated for Portuguese with eight components and each components with scores from 0 to 100: higher scores denote greater quality of life.</description>
          <population>Intention to treat analysis (ITT)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>scale</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 Functional Capacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" spread="22.7"/>
                    <measurement group_id="O2" value="55.8" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Functional Capacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="25.7"/>
                    <measurement group_id="O2" value="60.6" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Functional Capacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="22.3"/>
                    <measurement group_id="O2" value="66.6" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Functional Capacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" spread="20.8"/>
                    <measurement group_id="O2" value="71.6" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 Functional Capacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" spread="17.6"/>
                    <measurement group_id="O2" value="71.4" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Functional Capacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" spread="19.8"/>
                    <measurement group_id="O2" value="70.9" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 limitation in physical aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="26.5"/>
                    <measurement group_id="O2" value="16.3" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 limitation in physical aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" spread="37.9"/>
                    <measurement group_id="O2" value="30.6" spread="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 limitation in physical aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" spread="39.7"/>
                    <measurement group_id="O2" value="43.8" spread="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 limitation in physical aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" spread="36.2"/>
                    <measurement group_id="O2" value="55.0" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 limitation in physical aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" spread="33.7"/>
                    <measurement group_id="O2" value="56.3" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 limitation in physical aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" spread="31.8"/>
                    <measurement group_id="O2" value="55.8" spread="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="17.9"/>
                    <measurement group_id="O2" value="28.8" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" spread="24.9"/>
                    <measurement group_id="O2" value="44.8" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" spread="20.0"/>
                    <measurement group_id="O2" value="51.5" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" spread="20.3"/>
                    <measurement group_id="O2" value="53.6" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="22.7"/>
                    <measurement group_id="O2" value="54.6" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" spread="26.1"/>
                    <measurement group_id="O2" value="56.5" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 General Health State</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" spread="25.7"/>
                    <measurement group_id="O2" value="56.5" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 General Health State</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" spread="23.0"/>
                    <measurement group_id="O2" value="62.0" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 General Health State</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" spread="25.9"/>
                    <measurement group_id="O2" value="63.7" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 General Health State</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6" spread="20.9"/>
                    <measurement group_id="O2" value="60.4" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 General Health State</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" spread="22.2"/>
                    <measurement group_id="O2" value="58.4" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 General Health State</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" spread="22.9"/>
                    <measurement group_id="O2" value="63.4" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" spread="25.3"/>
                    <measurement group_id="O2" value="47.6" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="24.3"/>
                    <measurement group_id="O2" value="54.3" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" spread="23.1"/>
                    <measurement group_id="O2" value="57.1" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="19.4"/>
                    <measurement group_id="O2" value="52.8" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" spread="20.4"/>
                    <measurement group_id="O2" value="56.3" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="23.2"/>
                    <measurement group_id="O2" value="58.8" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 Social Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="34.6"/>
                    <measurement group_id="O2" value="65.9" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Social Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="27.7"/>
                    <measurement group_id="O2" value="75.6" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Social Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" spread="27.9"/>
                    <measurement group_id="O2" value="80.9" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Social Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4" spread="17.8"/>
                    <measurement group_id="O2" value="76.6" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 Social Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" spread="17.0"/>
                    <measurement group_id="O2" value="79.4" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Social Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" spread="17.4"/>
                    <measurement group_id="O2" value="82.5" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 Emotional Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" spread="41.3"/>
                    <measurement group_id="O2" value="62.5" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Emotional Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" spread="37.1"/>
                    <measurement group_id="O2" value="71.7" spread="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Emotional Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" spread="33.6"/>
                    <measurement group_id="O2" value="78.3" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Emotional Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" spread="32.0"/>
                    <measurement group_id="O2" value="80.0" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 Emotional Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" spread="24.7"/>
                    <measurement group_id="O2" value="73.3" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Emotional Aspects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="30.1"/>
                    <measurement group_id="O2" value="76.7" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" spread="22.0"/>
                    <measurement group_id="O2" value="58.5" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" spread="22.8"/>
                    <measurement group_id="O2" value="62.9" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" spread="19.2"/>
                    <measurement group_id="O2" value="66.3" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="19.5"/>
                    <measurement group_id="O2" value="65.1" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="20.6"/>
                    <measurement group_id="O2" value="63.7" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="22.5"/>
                    <measurement group_id="O2" value="65.2" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Likert Improvement Assessment Scale</title>
        <description>Likert improvement assessment scale is based on the patient’s opinion (LIKERT P) and assessor’s opinion (LIKERT A), categorized in 1=MB (much better), 2=SB (slightly better), 3=NC (no change), 4=SW (slightly worse) and 5=MW (much worse). This scale was was applied to each day of assessment. The numbers in the category titles represent the different days.</description>
        <time_frame>Days 0, 3, 7, 14 and 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acupuncture</title>
            <description>The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients were submitted to five non-penetrating acupuncture sessions in the placebo group (PG).</description>
          </group>
        </group_list>
        <measure>
          <title>Likert Improvement Assessment Scale</title>
          <description>Likert improvement assessment scale is based on the patient’s opinion (LIKERT P) and assessor’s opinion (LIKERT A), categorized in 1=MB (much better), 2=SB (slightly better), 3=NC (no change), 4=SW (slightly worse) and 5=MW (much worse). This scale was was applied to each day of assessment. The numbers in the category titles represent the different days.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Likert 0 P</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.54"/>
                    <measurement group_id="O2" value="2.15" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likert 0 A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.63"/>
                    <measurement group_id="O2" value="2.0" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likert 3 P</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.72"/>
                    <measurement group_id="O2" value="2.27" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likert 3 A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.66"/>
                    <measurement group_id="O2" value="2.17" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likert 7 P</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.72"/>
                    <measurement group_id="O2" value="2.20" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likert 7 A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.67"/>
                    <measurement group_id="O2" value="2.07" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likert 14 P</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.73"/>
                    <measurement group_id="O2" value="2.05" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likert 14 A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.73"/>
                    <measurement group_id="O2" value="2.12" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likert 21 P</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.8"/>
                    <measurement group_id="O2" value="2.07" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likert 21 A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.8"/>
                    <measurement group_id="O2" value="1.95" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Anti-inflammatory Tablets Taken</title>
        <description>Number of 50 mg sodium diclofenac pills taken per day</description>
        <time_frame>Days 3,7,14,21 and 28</time_frame>
        <population>Intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Acupuncture</title>
            <description>The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Patients were submitted to five non-penetrating acupuncture sessions in the placebo group (PG).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Anti-inflammatory Tablets Taken</title>
          <description>Number of 50 mg sodium diclofenac pills taken per day</description>
          <population>Intention to treat (ITT)</population>
          <units>number of pills/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.6"/>
                    <measurement group_id="O2" value="2.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="3.6"/>
                    <measurement group_id="O2" value="4.2" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="3.1"/>
                    <measurement group_id="O2" value="3.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.8"/>
                    <measurement group_id="O2" value="3.7" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="2.7"/>
                    <measurement group_id="O2" value="2.3" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious adverse events were collected during de follow-up (28 days).</time_frame>
      <desc>80 patients were evaluated in the end of the study and non-serious adverse events were observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Acupuncture</title>
          <description>The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Patients were submitted to five non-penetrating acupuncture sessions in the placebo group (PG).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0,001</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tatiana Molinas Hasegawa</name_or_title>
      <organization>Federal University of São Paulo</organization>
      <phone>55 115576 4239</phone>
      <email>tatianamolinas@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

